Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy

Area of Science:

• Immunology
• Nanomedicine
• Oncology

Background:

• Immune reactions to nanomedicines can negatively impact patient outcomes and treatment effectiveness.
• Type III interferon (IFN-λ) response to lipid nanoparticles complexed with nucleic acids (lipoplexes) was previously shown to influence nanomedicine distribution.

Purpose of the Study:

• To identify the cell types producing IFN-λ in response to lipoplexes and understand IFN-λ propagation mechanisms.
• To evaluate the impact of IFN-λ pretreatment on the accumulation of chemotherapeutic small molecules.
• To determine the optimal administration route for IFN-λ pretreatment and assess its efficacy in a murine tumor model.

Main Methods:

• Investigated cell-specific IFN-λ production following lipoplex exposure.
• Assessed alterations in doxorubicin accumulation after IFN-λ pretreatment.
• Compared different administration routes for IFN-λ pretreatment.
• Evaluated the effect of IFN-λ pretreatment on survival in a CT26 tumor-bearing mouse model treated with Doxil®.

Main Results:

• Identified specific cell types responsible for IFN-λ production in response to lipoplexes.
• Demonstrated that IFN-λ pretreatment alters the biodistribution of chemotherapeutic small molecules like doxorubicin.
• Subcutaneous administration of IFN-λ was found to be the most efficacious route.
• IFN-λ pretreatment significantly increased survival time in mice treated with Doxil®.

Conclusions:

• IFN-λ pretreatment represents a promising strategy to enhance nanomedicine tumor targeting and efficacy.
• This approach has the potential to improve current anti-cancer nanomedicine treatment protocols.
• The findings support the rapid clinical translation of IFN-λ-based strategies for cancer therapy.